Comparative Cohort Study of Long-term Safety Outcomes of Risankizumab Compared to Biologic Treatments for Ulcerative Colitis and Crohn’s Disease in a Real-world Setting in Sweden and Denmark First published 01/07/2024 Last updated 07/08/2025 EU PAS number:EUPAS1000000151 Study Ongoing